Phaseline

Companies › Curevo

Curevo: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Mar 2032.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Amezosvatein (CRV-101)
Herpes zoster vaccine
–Phase 2Herpes ZosterMar 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05304351Amezosvatein (CRV-101)Phase 2Herpes ZosterInfectious diseaseMar 2032

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Osivax Artcline Shanghai HEP Pharmaceutical BiomX Green Cross

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.